News >

High Response Rate in Histiocytic Disease With MEK Inhibition

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 03, 2018

Five patients remained on the 60-mg starting dose of cobimetinib. The dosage was reduced to 40 mg for 8 patients, and 2 patients had a reduced dosage to 20 mg.

“The safety and tolerability have been similar to other studies of cobimetinib,” Diamond said. “One patient was removed for toxicity, but none for intolerable side effects. The optimal duration and dosing of cobimetinib remain unknown.”
Diamond EL, Durham BH, Dogan A, et al. Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders. In: Proceedings from the 59th ASH Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA. Abstract 257.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication